Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in their shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
On May 7, 2013, the following individuals purchased Ordinary Shares at a price of 1,644.79 pence per share. These purchases resulted from the re-investment of dividends on shares held within an Individual Savings Account (ISA):
- Sir Andrew Witty: 45 shares
- Mr S M Bicknell: 99 shares
- Mr D S Redfern: 19 shares
- Mrs V A Whyte: 17 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: May 7, 2013
- Share Price: 1,644.79 pence per Ordinary Share
- Transaction Type: Dividend re-investment within an ISA
- Participants: Four senior executives, including CEO Sir Andrew Witty
- Notification Date: May 8, 2013